Pricing
  1. JP-listed companies
  2. TAIKO PHARMACEUTICAL CO., LTD.
  3. Financials
  4. Net income

TAIKO PHARMACEUTICAL CO., LTD. (4574)

Market cap
¥15.4B
P/E ratio
27.8x
Makes over-the-counter medicines like Seirogan and Cleverin infection control products, serving consumers and institutions across Japan and Asia.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndNet income (Million JPY)YoY (%)
Dec 31, 2025923+2.78%
Dec 31, 2024898-124.87%
Dec 31, 2023-3,611-26.23%
Dec 31, 2022-4,895-48.98%
Dec 31, 2021-9,594-349.09%
Dec 31, 20203,852+56.98%
Mar 31, 20202,453+73.33%
Mar 31, 20191,415+29.27%
Mar 31, 20181,095+4.34%
Mar 31, 20171,049+24.91%
Mar 31, 2016840-52.55%
Mar 31, 20151,771+15.30%
Mar 31, 20141,536+70.87%
Mar 31, 2013899+141.19%
Mar 31, 2012373

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat